Elanco Animal Health Future Growth
Future criteria checks 3/6
Elanco Animal Health is forecast to grow earnings and revenue by 90.4% and 4.1% per annum respectively. EPS is expected to grow by 95.9% per annum. Return on equity is forecast to be 9.2% in 3 years.
Key information
90.4%
Earnings growth rate
95.9%
EPS growth rate
| Pharmaceuticals earnings growth | 22.8% |
| Revenue growth rate | 4.1% |
| Future return on equity | 9.2% |
| Analyst coverage | Good |
| Last updated | 08 Aug 2024 |
Recent future growth updates
Recent updates
Investors Don't See Light At End Of Elanco Animal Health Incorporated's (NYSE:ELAN) Tunnel And Push Stock Down 27%
Jul 11
Elanco Animal Health: Pipeline Concerns Appear Overblown
Jun 30Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Jun 06Elanco Animal Health: At Least Fully Valued After Rally
Jun 05Benign Growth For Elanco Animal Health Incorporated (NYSE:ELAN) Underpins Its Share Price
Apr 22Elanco Animal Health (NYSE:ELAN) Seems To Be Using A Lot Of Debt
Feb 24Elanco Animal Health: A Solid Sale Addresses Leverage
Feb 09Elanco Animal Health Incorporated (NYSE:ELAN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 01Elanco Animal Health: Turning More Healthy
Dec 21Is Elanco Animal Health (NYSE:ELAN) A Risky Investment?
Nov 09Elanco Animal Health: Signs Of Stabilization, Amidst Still A Big Debt Pile
Oct 05Here's Why Elanco Animal Health (NYSE:ELAN) Is Weighed Down By Its Debt Load
Aug 02Elanco Animal Health: Seems Like A Decent Bet Right Now
Jul 25Elanco Animal Health: Robust Results Overshadowed By Persisting Challenges
Jul 14There's No Escaping Elanco Animal Health Incorporated's (NYSE:ELAN) Muted Revenues
Jun 09Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Feb 22Elanco Q4 2022 Earnings Preview
Feb 20Elanco's Tangible Equity Units: Living With The Worst Case
Dec 13We Think Elanco Animal Health (NYSE:ELAN) Is Taking Some Risk With Its Debt
Nov 08Elanco Q3 2022 Earnings Preview
Nov 07Elanco Animal Health: This 'Sick Dog' Should Recover
Oct 19Elanco adds 9% as activist investor Sachem Head raises stake
Sep 09Elanco Animal Health hits another 52-week low. What's going on with the company?
Aug 23Elanco Animal Health hits 52-week low; down 33% YTD
Aug 16Elanco Q2 2022 Earnings Preview
Aug 05We Think Elanco Animal Health (NYSE:ELAN) Is Taking Some Risk With Its Debt
Jul 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,852 | 147 | 764 | 839 | 8 |
| 12/31/2025 | 4,635 | 87 | 827 | 874 | 10 |
| 12/31/2024 | 4,457 | -25 | 612 | 613 | 10 |
| 3/31/2024 | 4,365 | -1,302 | 278 | 418 | N/A |
| 12/31/2023 | 4,417 | -1,231 | 117 | 271 | N/A |
| 9/30/2023 | 4,367 | -1,144 | -65 | 127 | N/A |
| 6/30/2023 | 4,324 | -113 | -87 | 118 | N/A |
| 3/31/2023 | 4,442 | -26 | 173 | 369 | N/A |
| 12/31/2022 | 4,411 | -78 | 268 | 452 | N/A |
| 9/30/2022 | 4,538 | -132 | 466 | 662 | N/A |
| 6/30/2022 | 4,644 | -171 | 387 | 562 | N/A |
| 3/31/2022 | 4,748 | -371 | 232 | 399 | N/A |
| 12/31/2021 | 4,764 | -483 | 286 | 483 | N/A |
| 9/30/2021 | 4,791 | -698 | -86 | 167 | N/A |
| 6/30/2021 | 4,550 | -729 | -366 | -34 | N/A |
| 3/31/2021 | 3,857 | -572 | -345 | -23 | N/A |
| 12/31/2020 | 3,271 | -574 | -352 | -41 | N/A |
| 9/30/2020 | 2,921 | -246 | -97 | 178 | N/A |
| 6/30/2020 | 2,802 | -101 | 147 | 330 | N/A |
| 3/31/2020 | 2,998 | -13 | 8 | 220 | N/A |
| 12/31/2019 | 3,071 | 68 | 27 | 224 | N/A |
| 9/30/2019 | 3,083 | 94 | 89 | 237 | N/A |
| 6/30/2019 | 3,073 | 144 | 207 | 362 | N/A |
| 3/31/2019 | 3,062 | 45 | 314 | 448 | N/A |
| 12/31/2018 | 3,067 | 87 | 351 | 487 | N/A |
| 9/30/2018 | 3,022 | -91 | 213 | 355 | N/A |
| 6/30/2018 | 2,958 | -172 | 122 | 267 | N/A |
| 3/31/2018 | 2,906 | -174 | 49 | 176 | N/A |
| 12/31/2017 | 2,889 | -311 | N/A | 174 | N/A |
| 12/31/2016 | 2,914 | -48 | N/A | 156 | N/A |
| 12/31/2015 | 2,909 | -211 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELAN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: ELAN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ELAN is expected to become profitable in the next 3 years.
Revenue vs Market: ELAN's revenue (4.1% per year) is forecast to grow slower than the US market (8.5% per year).
High Growth Revenue: ELAN's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ELAN's Return on Equity is forecast to be low in 3 years time (9.2%).